Login to Your Account

Aileron’s $30M Series E to ‘Activate’ Clinical Development

By Catherine Shaffer
Staff Writer

Monday, November 18, 2013
Aileron Therapeutics Inc., of Cambridge, Mass., will leverage a new $30 million financing round to advance its lead oncology candidate into the clinic and continue development of its other pipeline products. The funds will boost Aileron’s p53 re-activator, ALRN-6924, into clinical studies, and move forward the company’s Phase I long-acting growth hormone-releasing factor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription